123 related articles for article (PubMed ID: 8382870)
1. Cytomegalovirus infection and prophylaxis in heart transplantation.
Laske A; Gallino A; Carrel T; Niederhäuser U; von Segesser LK; Turina MI
Transplant Proc; 1993 Feb; 25(1 Pt 2):1427-8. PubMed ID: 8382870
[No Abstract] [Full Text] [Related]
2. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment?
Tenschert W; Gonnermann D; Meyer-Moldenhauer WH; Cremaschi L; Huland H
Transplant Proc; 1993 Dec; 25(6):3256-8. PubMed ID: 8266533
[No Abstract] [Full Text] [Related]
3. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
4. Incidence and therapy of cytomegalovirus disease after liver transplantation.
Wiens M; Lefèbre B; Blumhardt G; Schmidt CA; Lohmann R; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1985-6. PubMed ID: 8385829
[No Abstract] [Full Text] [Related]
5. Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients.
Meyers JD
Transplant Proc; 1991 Jun; 23(3 Suppl 3):139-42, discussion 142-3. PubMed ID: 1648819
[No Abstract] [Full Text] [Related]
6. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
7. Experience of cytomegalovirus infection in heart-lung transplant recipients.
Smyth RL; Scott JP; Higenbottam TW; Wreghitt TG; Stewart S; Fradet G; Clelland CA; Wallwork J
Transplant Proc; 1990 Aug; 22(4):1820-1. PubMed ID: 2167539
[No Abstract] [Full Text] [Related]
8. Cytomegalovirus infection during heart transplantation: assessment of a therapeutic protocol without prophylaxis.
Decoene C; Pol A; Dewilde A; Wattre P; Prat A; Stankowiak C; Warembourg H
Transplant Proc; 1995 Aug; 27(4):2523. PubMed ID: 7652913
[No Abstract] [Full Text] [Related]
9. Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation.
Laske A; Gallino A; Mohacsi P; Bauer EP; Carrel T; von Segesser LK; Turina MI
Transplant Proc; 1991 Feb; 23(1 Pt 2):1170-3. PubMed ID: 1846456
[No Abstract] [Full Text] [Related]
10. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
11. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma of donor-positive/recipient-negative serostatus.
Avery RK
Clin Infect Dis; 2007 Aug; 45(4):448-9. PubMed ID: 17638192
[No Abstract] [Full Text] [Related]
13. Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients.
Prokurat S; Drabik E; Grenda R; Vogt E
Transplant Proc; 1993 Aug; 25(4):2577. PubMed ID: 8395104
[No Abstract] [Full Text] [Related]
14. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
15. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
16. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG-Study Group.
George MJ; Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD
Transplant Proc; 1993 Oct; 25(5 Suppl 4):22-4. PubMed ID: 8212303
[No Abstract] [Full Text] [Related]
17. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
18. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR
Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746
[TBL] [Abstract][Full Text] [Related]
19. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus colitis in a pediatric heart transplant patient.
Etheridge SP; Bolman RM; Braunlin EA
Clin Transplant; 1994 Aug; 8(4):409-12. PubMed ID: 7949549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
